Zymeworks Inc. (ZYME)

Market Cap	760.08M
Revenue (ttm)	50.46M
Net Income (ttm)	-125.97M
Shares Out	70.70M
EPS (ttm)	-1.78
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	242,420
Open	10.82
Previous Close	10.63
Day's Range	10.63 - 11.01
52-Week Range	6.02 - 13.14
Beta	1.14
Analysts	Buy
Price Target	12.67 (+17.86%)
Earnings Date	Aug 1, 2024

About ZYME

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 28, 2017
• Employees: 278
• Stock Exchange: NASDAQ
• Ticker Symbol: ZYME

Analyst Forecast

According to 3 analysts, the average rating for ZYME stock is "Buy." The 12-month stock price forecast is $12.67, which is an increase of 17.86% from the latest price.

Price Target

$12.67

(17.86% upside)

Analyst Consensus: Buy